SGD Pharma advances glass packaging range in North America
Key takeaways
- SGD Pharma collaborates with Prince Sterilization Services to introduce My Sterinity Nasal vials for North America.
- The RTU Type I glass vials cater to the growing nasal drug delivery market, offering enhanced purity and sterility assurance.
- Produced at SGD Pharma’s Saint-Quentin-La-Motte facility, the vials ensure quality and supply chain reliability for US biopharma customers.
SGD Pharma has partnered with Prince Sterilization Services to validate Ready-to-Use (RTU) Type I glass primary packaging solutions for the North American market.
The companies have launched the My Sterinity Nasal platform, a flexible cleaned vial range part of SGD Pharma’s My Sterinity RTU platform using the company’s U-Save Type I vials.
The vials are said to be designed to support the expanding segment of high-value nasal drug delivery. They are initially available in 3.5 mL, 7.5 mL, and 10 mL formats in clear and amber glass.
The provider of pharmaceutical glass packaging says that the benefits of My Sterinity Nasal include:
- Controlled particulate and endotoxin levels for enhanced purity
- Biologically inert Type I sterile glass, with no need for preservatives (reducing inflammation risk)
- Validated sterility assurance
- Compatibility with standard nasal preservative-free pump systems
- Packaged in double-bagged trays for RTU presentation.
“The new My Sterinity Nasal vials support sensitive nasal drug delivery thanks to high-quality primary packaging, which protects the drug and ensures its stability, safety, and efficacy,” the company adds.
The range will be produced at the SGD Pharma’s flagship Saint-Quentin-La-Motte manufacturing facility in northern France. Prince will provide washing, depyrogenation, and sterilization services in North America to ensure a validated, regional supply chain for US biopharmaceutical customers.
Glass for nasal medicine packs
SGD Pharma outlines that the global nasal market is valued at €9 billion (US$10.4 billion) with more than two billion units, and that it has historically been dominated by plastic, accounting for around 88% of packaging material use.
The company says that glass offers greater chemical inertness, barrier protection, and long-term biocompatibility, which is critical for preserving product integrity, minimizing adsorption, and ensuring sterility in chronic-use therapies.
Carole Grassi, chief commercial marketing and innovation officer at SGD Pharma, comments: “Our collaboration with Prince marks an important milestone in SGD Pharma’s innovation growth strategy for North America.”
“The My Sterinity Nasal platform represents a major step forward in high-value nasal drug delivery, and our collaboration with Prince unlocks immediate US-qualified capacity for biopharma customers scaling complex nasal therapy programs. This is more than a product launch, it is a validated supply chain ready to support qualification, clinical trials, and commercial launch with unmatched speed and reliability.”
Daniel Prince, CEO at Prince, adds: “SGD Pharma’s Type I glass expertise combined with our quality-focused and flexible RTU and sterilization platform creates the gold standard for sterile nasal packaging.”
“Prince’s recent US qualification means we can now deliver RTU, terminally sterilized My Sterinity Nasal vials in timelines that match domestic and international customer development cycles and exceed quality requirements.”
At the ongoing DCAT 2026 pharmaceutical trade show in New York City, US (March 23–26), SGD Pharma is presenting its glass packaging portfolio designed to enhance drug integrity, patient safety, and operational efficiency.
